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COX-2; TAL; sulprostone, Coxibs; EP3 antagonist CYCLOOXYGENASE-2 (COX-2), a rate-limiting enzyme that catalyzes the conversion of arachidonic acid to prostanoids, is expressed in the thick ascending limb of Henle's loop (TAL) of the renal cortex and outer medulla. This inducible enzyme, which contributes to the maintenance of renal function and is regulated by vasoactive hormones and dietary sodium intake, is recognized as a constitutively expressed enzyme in a subset of TAL cells in the adult renal cortex and medulla of several species (19, 51) . COX-2 expression is regulated by glucocorticoids (49) , in vivo treatment with furosemide (28), sodium intake (28, 54) , bradykinin (40) , reactive oxygen species (24) , angiotensin II (8, 55) , and TNF-␣ (14, 15) . Moreover, induction of COX-2 associated with postnatal development, and following adrenalectomy, treatment with ramipril, and ingestion of a low-salt diet exhibit a defined axial expression pattern proceeding from the cortex to medulla (30, 32, 49) .
It is well established that COX-2 contributes to the regulation of many biological processes in mammalian tissues by increasing the synthesis of prostaglandin E 2 (PGE 2 ), a major renal metabolite involved in the regulation of salt balance (18) and volume control functions (42) . The diverse biological actions of PGE 2 are mediated by activation of four receptor subtypes, EP1-4, which are expressed in a tissue-and cellspecific manner (6) . In the kidney, EP3 and EP1 receptors are expressed in the medullary and cortical collecting ducts (17) , whereas it has been described that the TAL expresses EP3 but not EP1 (6, 12, 17) . This receptor is a well-characterized G protein-coupled receptor that signals mainly via inhibitory G (G i ), diminishing adenylate cyclase activity and lowering intracellular cAMP levels (46) , although a pertussis toxininsensitive, non-G i /G o pathway has also been identified (2) . Recently, EP3 has been linked to nondamaging modulatory effects, including attenuation of myocardial injury during ischemiareperfusion (35) , and as a negative modulator of allergic inflammation reactions (31) .
The regulation of COX-2 expression is complex and not completely understood, although COX-2 gene transcription is regulated by several specific transcription factors that bind to cis elements in the promoter region of the COX-2 gene depending on the cell type and stimulus (20, 44) . COX-2 also is regulated by posttranscriptional mechanisms and is subject to negative feedback inhibition through the peroxisome proliferator-activated receptor (PPAR␦), for example (23) . Interestingly, expression of COX-2 in the kidney is upregulated by selective COX-2 inhibitors (21, 28) . The ability of COX-2 inhibition to increase COX-2 expression also was observed when mouse M-1 cortical collecting duct cells were treated with NS-398 (38) . To further explore feedback inhibition of COX-2, we hypothesize that regulation of COX-2 expression is mediated by PGE 2 , its enzymatic product. Since EP3 receptors are the predominant receptor subtype expressed in the TAL, we postulate that PGE 2 downregulates COX-2 expression by a negative feedback loop involving EP3 receptors in this segment of the nephron. ) was administered by osmotic minipumps implanted subcutaneously. Two protocols were performed using sulprostone and Coxibs. In the prevention protocol, sulprostone was administered for 7 days, starting 2 days before treatment with Coxib for 5 days (Sulp7-Coxib5 group). Control groups consisted of sham rats and rats treated with sulprostone alone for 7 days. In the regression protocol, animals were treated with Coxib for 10 days; after 5 days of Coxib treatment, sulprostone was administered for 5 days (days 5-10; Coxib10-Sulp5 group). Sham rats and rats treated with sulprostone alone for 5 days were used as controls. Sulprostone was purchased from Cayman Chemical (Ann Arbor, MI), and celecoxib and rofecoxib were purchased from a local pharmacy. An additional protocol was done using a specific EP3 receptor antagonist, L-798106 (3, 26, 53) . Rats were infused with L-798106 at a dose of 100 g·kg Ϫ1 ·day Ϫ1 by osmotic pumps for 5 days; control rats were infused with vehicle. At the end of the infusion, the kidneys were removed under anesthesia and processed for histology, immunohistochemistry, morphometric analysis, Western blot analysis, and real-time RT-PCR.
METHODS

Animals
Localization of EP3 and EP1 receptors. Prostaglandin E 2 EP1 and EP3 receptors were localized in normal renal tissue using specific antibodies with the immunoperoxidase method in a singleimmunostaining protocol and in a double-immunostaining protocol by colocalization in the same sections of EP1 or EP3 receptors with Tamm-Horsfall glycoprotein, a TAL-specific marker, as previously described (49) .
Tissue processing and immunohistochemical analysis. Renal tissue samples (3-mm thick) were fixed by immersion in Bouin's solution for 24 h at room temperature. The tissue was then dehydrated, embedded in Paraplast Plus, serially sectioned at 5-m thickness with a Leica rotatory microtome, mounted on glass slides, and stored. Immunostaining was performed using an indirect immunoperoxidase technique as previously described to localize COX-2 in rat kidneys (33, 49) . Briefly, tissue sections were dewaxed, rehydrated, rinsed in 0.05 M Tris-phosphate-saline (TPS) buffer, pH 7.6, and incubated overnight at 22°C with a primary antiserum raised against COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA). The secondary antibody (Santa Cruz Biotechnology) and corresponding peroxidase-anti-peroxidase (PAP) complex (MP Biomedicals, Aurora, OH) were applied for 30 min each at 22°C. The immunoperoxidase reaction was visualized after incubation of sections in 0.1% (wt/vol) diaminobenzidine and 0.03% hydrogen peroxide. The sections were rinsed with TPS buffer between incubations, counterstained with hematoxylin, dehydrated and cleared with xylene, and then coverslipped. Controls for the immunostaining procedure were prepared by omission of the first antibody or by replacing it with preimmune serum. Tissue samples from all groups were coded and studied independently by two observers (C. P. Vio and C. Cespedes) in a blinded fashion; sections selected at random were used for each animal, and four fields per section were studied. Images were examined with conventional light microscopy and Nomarski differential interference contrast (DIC) microscopy as described (49) and acquired using a Nikon Eclipse E600 microscope and Nikon DXM1200 digital camera. The COX-2-stained area in each image was quantified utilizing computer-assisted image-analysis software (Simple PCI, Hamamatsu). The values corresponding to total immunostained cells were averaged and expressed as the mean absolute values per square micron, as previously described (33) . Indirect immunofluorescence staining was performed similar to the peroxidase method, but after incubation with the primary antibody sections were incubated with a fluorescent-labeled Alexa Fluor 488 secondary antibody (Invitrogen, Eugene, OR). Tissues were studied and images captured with an Olympus BX51 fluorescence microscope and ProgRes C5 digital camera (Jenoptik).
Double immunolabeling. This technique was performed as previously described (49) . Briefly, sections were incubated overnight at 22°C with the first primary antibody, the anti-EP1 receptor (catalog no. 107740) or anti-EP3 receptor (catalog no. 101760, both from Cayman Chemical), followed sequentially by the unlabeled secondary antibody, the PAP complex, and diaminobenzidine/hydrogen peroxide for color development, yielding a brown color. Incubation in 3% hydrogen peroxide/methanol for 20 min eliminated any remaining peroxidase activity. Subsequently, the second primary antibody, antiTamm-Horsfall glycoprotein (catalog no. 1011481, Cappel, Cooper Biomedical, West Chester, PA), was applied overnight at 22°C, followed by the unlabeled secondary antibody, PAP complex, and Vector SG substrate (catalog no. SK-4700, Vector Laboratories, Burlingame, CA) as the second reagent for color development, yielding a blue reaction product. The sections were dehydrated and cleared with xylene and then coverslipped, without hematoxylin counterstaining.
Western blotting. Western blotting was performed as described earlier (4, 48) . Briefly, kidney sections weighing 100 mg were prepared with an Ultra-Turrax homogenizer in a lysis buffer containing 100 mM Tris·HCl, pH 7.6, 5 mM EDTA, 1% SDS, and 1 M PMSF; protein concentration was determined using the Bradford method. Protein extract (40 g total) was mixed with sample buffer (100 mM Tris·HCl, pH 6.8, 200 mM dithiotreitol, 4% SDS, 0.2% bromophenol blue, and 20% glycerol) and boiled for 5 min. Proteins were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked using 5% skim milk in TTBS (Tris-buffered saline and Tween 20) for 1 h at room temperature and incubated with a primary antibody against COX-2 (Cayman Chemical) for 18 h at 4°C, washed in TTBS, and incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody goat anti-rabbit (Santa Cruz Biotechnology) for 1 h at room temperature. Immunoreactivity was detected using Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL). The blots were scanned, and densitometric analysis was performed using ImageJ software; ␤-tubulin was used to normalize protein expression.
Quantitative RT-PCR. Total RNA was isolated from kidney tissue using TRIzol (41) (GIBCO BRL, Life Technologies, Grand Island, NY). RNA concentration was determined by absorbances at 260/280 nm, and an initial concentration of 20 g/l was used for cDNA synthesis. Samples were treated with RQ1 RNase-Free DNase (Promega, Madison WI), and to obtain cDNA RT-PCR was performed using the GoScript Reverse Transcription System (5) (Promega). Determination of mRNA abundance of specific genes was assessed by quantitative PCR (qPCR), using the StepOne 48-well Real-Time PCR System (Applied Biosystems, Carlsbad, CA) and Fast SYBR Green Master Mix (Applied Biosystems) reagent for amplification, using 4 l cDNA, 4 l DEPC water, 10 l Master Mix, 1 l Reverse Primer, and 1 l Forward Primer, for a total volume of 20 l/well (9). The housekeeping gene (7) used in this tissue was GAPDH (forward primer: 5=-CACGGCAAGTTCAACGGC-3=; reverse primer 5=-GGTGGTGAAGACGCCAGTA-3=) at an annealing temperature of 60°C, and a posterior PCR product analysis by Melting curve and a 2% agarose gel electrophoresis. For COX-2, primer sequences used were the following: forward primer: 5=-TGTATGCTACCATCTG-GCTTCGG-3=, reverse primer 5-=GTTTGGAACAGTCGCTCGT-CATC-3=. Final mathematical quantification was made using the 2(Ϫ⌬⌬CT) method, and submitted to ANOVA statistical analysis, followed by Dunnett's multiple comparison test (13) .
Statistical methods. ANOVA followed by Tukey's test was used for comparisons among groups. Values were expressed as means Ϯ SE, and statistical tests were performed using GraphPad Prism software, version 5.0 (GraphPad Software, San Diego, CA).
RESULTS
Coxib treatment increases the number of COX-2-expressing cells in the TAL.
Overall inspection of the renal cortex and outer medulla from sham rats revealed that COX-2-positive staining was found exclusively in small and scattered groups of tubular epithelial cells corresponding to cortical and medullary TAL. Interestingly, some of these heavily stained COX-2-expressing cells are located next to a few unstained neighboring tubular epithelial cells, as described in our previous studies (40, 49, 51). After treatment with highly selective Coxibs, there were striking differences in the number of cells containing COX-2 compared with the sham group. Examination by DIC Nomarski and fluorescence microscopy showed that the number of cells displaying COX-2 staining increased dramatically in rats given Coxib for 5 days compared with sham rats. The increase in COX-2 expression was observed in a defined manner, occurring axially from the cortex to the medulla, which likely reflects recruitment of COX-2-expressing cells from a pool of TAL cells that do not express COX-2 under basal conditions (Fig. 1) . Similar results were obtained when rats were treated with rofecoxib or celecoxib, indicating that recruitment of COX-2-expressing TAL cells is evident in response to two different Coxibs.
Activation of EP3 inhibits COX-2 expression induced by Coxibs. As COX-2 expression in the TAL is under tonic inhibition by endogenous glucocorticoids (25, 34), we postulated its expression also might be regulated by other mechanisms. Accordingly, the EP3-selective analog sulprostone was used to test the hypothesis that autocrine feedback inhibition of COX-2 in the TAL is mediated by its enzymatic product, PGE 2 , since EP3 receptors are the predominant receptor subtype expressed in this nephron segment. The number of TAL cells expressing COX-2 was significantly reduced in response to the prevention protocol, in which sulprostone was administered 2 days before and then concurrently with Coxib treatment (Fig. 2, A and B) . Application of the regression protocol, the administration of sulprostone in addition to continuing Coxib treatment for 10 days, also significantly diminished the number of cells positive for COX-2 staining in response to Coxib treatment (Fig. 2, A and B) . Collectively, the data suggest activation of EP3 by sulprostone opposes the increase in COX-2-expressing TAL cells induced by treatment with a Coxib. Moreover, EP3 activation both prevents and reverses COX-2 expression induced by Coxibs.
Effects of sulprostone on COX-2 protein expression induced by Coxibs. Western blot analysis was performed using total kidney tissue to examine the effects of both Coxibs and sulprostone on COX-2 protein expression in the kidney. Expression of COX-2, evaluated as COX-2 protein normalized to ␤-tubulin levels, was significantly increased after treatment with Coxibs for Fig. 3 . Effects of Coxib and sulprostone on COX-2 protein expression. Densitometric analysis of COX-2 Western blots shows that COX-2 expression significantly increased following Coxib treatment. The effect was prevented by sulprostone administration (prevention protocol); similarly, in the regression protocol, treatment with Coxib increased COX-2 protein whereas the administration of sulprostone decreased COX-2 to sham levels. A representative Western blot is shown. *P Ͻ 0.05; n ϭ 4. Fig. 4 . Sulprostone inhibits increases in COX-2 mRNA induced by Coxib. COX-2 mRNA accumulation as measured by quantitative RT-PCR, increased in response to Coxib treatment. The effect was both prevented and reversed by the coadministration of sulprostone. GAPDH was used to normalize COX-2 mRNA levels. *P Ͻ 0.05; n ϭ 5. 5 or 10 days compared with the basal COX-2 protein levels of the sham groups (Fig. 3) . The elevated COX-2 expression was abolished in response to sulprostone administered by either the prevention or regression protocols (Fig. 3) . These data are consistent with the immunohistochemical analysis and support the notion that activation of EP3 exerts an inhibitory effect on renal COX-2 expression.
Coxib-mediated increases in COX-2 mRNA accumulation are inhibited by sulprostone. COX-2 mRNA accumulation was measured by qRT-PCR to investigate whether the upregulation of COX-2 expression corresponded to a possible increase in COX-2 gene transcription and/or mRNA stability. Treatment with Coxib for 5 or 10 days increased COX-2 mRNA accumulation, an effect that was inhibited when sulprostone was administered by either the prevention or regression protocols (Fig. 4) . These results are in accord with the morphological and protein analyses, which showed that the increased COX-2 expression is inhibited by EP3 receptor activation.
Inhibition of EP3 receptors increases COX-2 protein expression and mRNA accumulation.
To further test the hypothesis that activation of EP3 receptors suppresses COX-2 expression in the TAL, renal sections from rats infused with the EP3 antagonist L-798106 were immunostained for COX-2. Morphometric analysis revealed that while few cells express COX-2 in the sham group, treatment with L-798106 increased the number of COX-2-expressing cells approximately threefold (Fig. 5, A and B) . These results were confirmed by Western blot analysis, which also indicated that COX-2 expression increased about threefold after treatment with L-798106 (Fig. 6, A  and B) . The increase in COX-2 protein expression was associated with a significant increase in COX-2 mRNA accumulation, as measured by qRT-PCR (Fig. 7) .
PGE 2 EP3, but not EP1, receptors are expressed in the TAL. The presence of EP3 receptors was observed in specific tubular segments, contrasting with the unstained background (Fig. 8A) and concentrated in the apical pole as shown in the inset at higher magnification (Fig. 8B) . The use of a double-immunostaining protocol by colocalization in the same sections shows staining of EP3 receptors in cells that express Tamm-Horsfall glycoprotein, a TAL cell-specific protein (Fig. 8C) . More detailed information on the inset is provided at higher magnification in Fig. 8D . EP1 receptors were localized to arteries near the juxtaglomerular apparatus, contrasting with the unstained background Fig. 9A . The use of double immunostaining showed that EP1 receptors (brown) are absent in the TAL segment, which is stained positive for the Tamm-Horsfall glycoprotein (blue) at higher magnification (Fig. 9B) .
DISCUSSION
The present study is the first to demonstrate that PGE 2 participates in a negative feedback loop in the TAL via activation of EP3 receptors. We demonstrated that COX-2 is constitutively expressed in TAL epithelial cells in the normal kidney and that administration of Coxibs or a selective EP3 antagonist increased the number of COX-2-expressing cells in a defined pattern along the TAL. The increase in COX-2 was confirmed by Western blot analysis, which showed a substantial increase in COX-2 protein expression in response to treatment with Coxibs or EP3 antagonism, in association with an increase in COX-2 mRNA accumulation. Moreover, the increases in COX-2 expression and mRNA accumulation in response to treatment with Coxibs were inhibited by administration of the synthetic PGE 2 analog and EP3 receptor selective agonist sulprostone.
The understanding of COX-2 biology has evolved from descriptions of an enzyme that is absent in normal conditions and inducible only in pathological conditions, to an enzyme constitutively expressed in some tissues under normal conditions and contributing to important physiological processes such as renal development and sodium handling. Studies have addressed the mechanisms that underlie the stimulation of COX-2 by diverse stimuli, including cytokines, LPS, and tumor promoters (10, 16) . COX-2 also is subject to feedback regulation by several mechanisms acting at both the transcriptional and posttranscriptional levels. Additionally, increases in cAMP induced via activation of EP2 were part of a positive feedback loop in renal Madin-Darby canine kidney cells (45) .
The features of the negative feedback regulation of de novo COX-2 expression include an increase in COX-2 that was abolished by pretreatment with sulprostone (prevention protocol) and returned to control levels when sulprostone was administered after treatment with Coxibs had already begun (regression protocol). An important feature of the Coxibmediated increase in COX-2 expression is an increase in the number of COX-2-expressing TAL cells in a well-defined manner along the tubule. Moreover, it is noteworthy that computer-assisted morphometric determinations revealed that the inhibitory effect of sulprostone treatment, using either protocol, also was a function of the decrease in the number of cells expressing COX-2. These features are consistent with the notion that a recruitment phenomenon in which subtypes of TAL cells, which do not express COX-2 under basal conditions, are induced to express the enzyme in response to an appropriate stimulus.
The increase in COX-2 expression associated with recruitment of TAL cells is not the only example of such a regulatory mechanism in the kidney. Indeed, features of COX-2 expression along the TAL are similar to those observed for renin (negative feedback loop) by angiotensin II, whereby inhibition of its production by ACE inhibition or effects via AT 1 receptor blockade increase renin in association with recruitment of afferent arteriole cells (30) . Conversely, angiotensin II decreases renin expression and the number of renin-expressing cells (36) . The renin-like recruitment phenomenon of COX-2 is defined by the modification in the number of COX-2-producing cells in which initially nonexpressing TAL cells are switched to become COX-2-positive cells. This reversible process, evident by lower COX-2 levels after sulprostone treatment via the regression protocol, may be responsible for alterations in PGE 2 synthesis and subsequent autocrine/juxtacrine signaling along the TAL. Moreover, our data are in agreement with previous studies in which COX-2 inhibition decreased urinary prostaglandin levels in association with increased COX-2 protein expression. The same dose of Coxib used in both studies caused an increase in COX-2 mRNA expression and blunted urinary prostaglandin excretion below control levels after 5 and 7 days of treatment (27, 29) . Since COX-2-derived prostanoids modulate homeostatic renal responses that regulate salt and water balance, the increased expression of COX-2 following treatment with a Coxib may relate to the maintenance of a minimal level of COX-2 expression required to counteract noxious effects due to salt and water overload. While this concept requires further investigation, it is interesting to note that sodium excretion tends to increase within a few days in patients with normal kidney function taking COX-2 inhibitors (43, 52) . The extent to which synthesis of additional COX-2 molecules contributes to this observation remains to be determined.
EP3, a well-described receptor expressed in TAL (6, 17, 22) , is novel among EP receptors by virtue of alternative spliced variants with different affinities for PGE 2 . It is important to note that although sulprostone may activate EP1 as well as EP3, TAL cells do not express the EP1 subtype, suggesting that the effects of this agonist in the present study are via activation of EP3. Moreover, data in the present study support the notion that EP1 receptors are not expressed in the TAL. The EP3 receptor, a mainly G i -type G protein-coupled receptor that has high affinity for PGE 2 and sulprostone, inhibits adenylate cyclase and cAMP levels but also may signal through a pertussis toxin-insensitive, non-G i /G o pathway (2) . This results in an upregulation of PLA 2 , facilitating arachidonic acid release and PGE 2 production (47). Activation of EP3 receptors also stimulates the MAPK and phosphatidylinositol 3-kinase pathways, increasing Erk and Akt concentrations, respectively (37), Wnt signaling, which inhibits GSK-3␤, and activates small Rho GTPases (1, 11) . Activation of EP3 may be involved in maintaining a critical level of PGE 2 synthesis in the TAL, which prevents excessive expression of COX-2 under normal conditions. In the presence of Coxibs, decreases in PGE 2 levels may facilitate de novo COX-2 gene transcription and/or enhance mRNA stability to increase protein expression, which would result in a return of PGE 2 to basal levels. Moreover, the basal expression pattern of COX-2 expression along the TAL may be indicative of a juxtacrine effect, whereby COX-2-positive cells producing PGE 2 suppress COX-2 expression by adjacent TAL cells. This concept is supported by data showing that activation of EP3 by sulprostone suppresses Coxib-mediated axial increases in COX-2 expression, and the observation that a few COX-2-expressing cells remain resistant to the suppressive effect of sulprostone, as well as dexamethasone, as previously reported (39) .
The present findings suggest that activation of the EP3 receptor in the TAL is part of the mechanism by which COX-2 expression, induced by Coxibs, is downregulated. However, the regulation of COX-2 is multifaceted and context dependent, and PGE 2 levels may not always be sufficient to regulate COX-2 expression. For instance, sustained upregulation of renocortical COX-2 and urinary PGE 2 levels was observed in response to administration of a low-salt diet (19, 27) . Since low salt intake does not increase COX-2 levels in the medulla, the mechanisms by which Coxibs increase COX-2 recruitment, mRNA accumulation, and protein expression may be distinct from those induced by low salt. The regulation of COX-2 by different mechanisms may be related to various functions of COX-2 along the nephron, and COX-2 expression in basally and newly expressing cells may be important for long-term physiological regulation via modifying the number of COX-2-positive cells in the TAL. Collectively, data in the present study are consistent with the concept that COX-2 in TAL segments is regulated by a negative feedback loop by its product, PGE 2 , acting on the EP3 receptor.
